For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 0 |
| Research and development | 340,562 | 757,248 | 377,789 | 325,623 |
| General and administrative | 355,070 | 557,866 | 363,426 | 370,150 |
| Total expenses | 695,632 | 1,315,114 | 741,215 | 695,773 |
| Loss from operations | -695,632 | -1,315,114 | -741,215 | -695,773 |
| Interest income | 9,207 | 19,749 | 29,031 | 35,831 |
| Net loss | -686,425 | -1,295,365 | -712,184 | -659,942 |
| Basic EPS | 0 | -0.008 | 0 | 0 |
| Diluted EPS | 0 | -0.008 | 0 | 0 |
| Basic Average Shares | 172,573,545 | 172,576,969 | 172,573,545 | 172,573,545 |
| Diluted Average Shares | 172,573,545 | 172,576,969 | 172,573,545 | 172,573,545 |
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)